Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析

◆英語タイトル:Dicerna Pharmaceuticals Inc (DRNA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH93530FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver such as rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Cambridge, Massachusetts, the US.

Dicerna Pharmaceuticals Inc Key Recent Developments

Apr 01,2021: Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30,2021: Dicerna’s GalXC-Plus RNAi Technology delivers target knockdown across CNS and to specific CNS cell types in preclinical studies
Mar 24,2021: Dicerna to present new GalXC-Plus nonclinical CNS data at Oligonucleotide and Precision Therapeutics Virtual Congress
Mar 05,2021: Dicerna and Roche commence Hepatitis B virus therapeutic trial

This comprehensive SWOT profile of Dicerna Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Dicerna Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Dicerna Pharmaceuticals Inc – Key Information
Dicerna Pharmaceuticals Inc – Overview
Dicerna Pharmaceuticals Inc – Key Employees
Dicerna Pharmaceuticals Inc – Key Employee Biographies
Dicerna Pharmaceuticals Inc – Key Operational Heads
Dicerna Pharmaceuticals Inc – Major Products and Services
Dicerna Pharmaceuticals Inc – History
Dicerna Pharmaceuticals Inc – Company Statement
Dicerna Pharmaceuticals Inc – Locations And Subsidiaries
Dicerna Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Dicerna Pharmaceuticals Inc – Business Description
Dicerna Pharmaceuticals Inc – Corporate Strategy
Dicerna Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Dicerna Pharmaceuticals Inc – Strengths
Dicerna Pharmaceuticals Inc – Weaknesses
Dicerna Pharmaceuticals Inc – Opportunities
Dicerna Pharmaceuticals Inc – Threats
Dicerna Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Dicerna Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Dicerna Pharmaceuticals Inc, Key Information
Dicerna Pharmaceuticals Inc, Key Ratios
Dicerna Pharmaceuticals Inc, Share Data
Dicerna Pharmaceuticals Inc, Major Products and Services
Dicerna Pharmaceuticals Inc, History
Dicerna Pharmaceuticals Inc, Key Employees
Dicerna Pharmaceuticals Inc, Key Employee Biographies
Dicerna Pharmaceuticals Inc, Key Operational Heads
Dicerna Pharmaceuticals Inc, Other Locations
Dicerna Pharmaceuticals Inc, Subsidiaries
Dicerna Pharmaceuticals Inc, Key Competitors
Dicerna Pharmaceuticals Inc, SWOT Analysis
Dicerna Pharmaceuticals Inc, Ratios based on current share price
Dicerna Pharmaceuticals Inc, Annual Ratios
Dicerna Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Power Clean Energy Development Co Ltd (735):電力:M&Aディール及び事業提携情報
    Summary China Power Clean Energy Development Co Ltd (CPCE) formerly China Power New Energy Development Co Ltd, is an electric utility. It develops, constructs, owns, operates, and manages clean energy power plants. The company produces electricity through natural gas, wind, hydro, and solar sources. …
  • Randox Laboratories Ltd:企業の製品パイプライン分析2018
    Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories. The company’s products include biochip analyzers, biochip immunoassays, clinical chemistry analyzers and diagnostic reagents among others. It offers …
  • Marubeni Corp (8002):企業の財務・戦略的SWOT分析
    Marubeni Corp (8002) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Antibe Therapeutics Inc (ATE):製薬・医療:M&Aディール及び事業提携情報
    Summary Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen deriv …
  • Pangaea Biotech SL:企業の製品パイプライン分析2018
    Summary Pangaea Biotech SL (Pangaea) is a provider of molecular diagnostics and research and development services for cancer treatment. The company discovers and develops gene signatures and prognostic markers. Its services include molecular diagnosis, in vitro drug testing, clinical trials, biomark …
  • Sumitomo Corporation:企業の戦略・SWOT・財務分析
    Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sberbank Rossii:企業の戦略・SWOT・財務情報
    Sberbank Rossii - Strategy, SWOT and Corporate Finance Report Summary Sberbank Rossii - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Molinos Rio de la Plata SA (MOLI3):企業の財務・戦略的SWOT分析
    Molinos Rio de la Plata SA (MOLI3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Health Net, LLC.:企業の戦略・SWOT・財務分析
    Health Net, LLC. - Strategy, SWOT and Corporate Finance Report Summary Health Net, LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Seelos Therapeutics, Inc. (SEEL):企業の財務・戦略的SWOT分析
    Seelos Therapeutics, Inc. (SEEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Chevron Canada Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Chevron Canada Ltd (CCL), a subsidiary of Chevron Corporation is an oil and gas company that refines and produces oil and natural gas products. The company explores, develops, produces and markets crude oil, natural gas and natural gas liquids. Its activities include drilling, facilities, ic …
  • Nestle Health Science SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Nestle Health Science SA (Nestle Health), a subsidiary of Nestle SA, is a health science company that manufactures nutritional and medicinal products derived from botanical plants. The company provides nutritional therapies for chronic conditions related to gastrointestinal diseases, aging p …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SteadyMed Therapeutics Inc:製品パイプライン分析
    Summary SteadyMed Therapeutics Inc (SteadyMed), a subsidiary of SteadyMed Ltd is a pharmaceutical company that develops and commercializes therapeutic product candidates. The company provides patchpump, a customizable, pre-filled, and pre-programmed disposable parenteral delivery platform for large …
  • Banco Nacional de Obras y Servicios Publicos SNC:企業の戦略・SWOT・財務分析
    Banco Nacional de Obras y Servicios Publicos SNC - Strategy, SWOT and Corporate Finance Report Summary Banco Nacional de Obras y Servicios Publicos SNC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • Absa Bank Ltd:企業の戦略・SWOT・財務分析
    Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • IntegraGen SA (ALINT):医療機器:M&Aディール及び事業提携情報
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • Helen of Troy Ltd:企業の戦略・SWOT・財務情報
    Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report Summary Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Ocular Therapeutix Inc (OCUL):製薬・医療:M&Aディール及び事業提携情報
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆